Virometix AG is a privately held clinical stage biotechnology company developing new generation synthetic vaccines for the prevention and treatment of infectious diseases and cancer
Management
Anna Sumeray
Chief Executive Officer
Anna Sumeray has over 25 years of experience in the life sciences sector with a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.
Anna’s diverse experiences include the build of a successful European biotech business for a US-based company from the ground up and management of Novartis’s oncology businesses in Finland and Germany. She also has significant M&A and licensing experience and was global head of business development and licensing at Novartis Ophthalmics. She has worked in 13 countries and in 4 languages.
Anna has a BSc (Hons) in Biochemistry from the University of Birmingham, UK and an MBA from INSEAD, Fontainebleau, France.
Lilli Stergiou
Chief Scientific Officer
Lilli Stergiou has 20 years of research and development experience in multiple fields including all areas of interest to Virometix – vaccines, infectious diseases, and oncology. She has a PhD in Molecular Biology and Genetics from the University of Zurich. Lilli joins Virometix from Redbiotec AG, where she was CSO, headed the HSV-2 Therapeutic Vaccine Program and built a pipeline based on Live Biotherapeutics for applications in oncology.
Sasan Navid
Chief Financial Officer
Sasan Navid has over 30 years of experience in the finance sector. He previously worked at Amgen Inc., where he held various positions within finance in the US and in Europe. Prior to Amgen, Sasan spent eight years with Ernst & Young in the firm’s audit group. He holds a B.S. degree in Accounting and a M.S. degree in Taxation from California State University Northridge.
Board of Directors
Harry Welten, MBA
Chairman
Over the last 17 years, Mr. Welten was Chief Financial Officer of both public as well as venture capital financed biotech companies. During that time, he has raised more than CHF320 million through IPO, venture capital, M&A as well as debt offerings. He now serves as Chairman or Member on the Board of Directors of several biotechnology companies in Switzerland, Belgium and the USA. He has degrees in Banking, Finance and Economics as well as an MBA (hons.) from Columbia University, NY, USA.
Axel Polack, PD Dr. med.
Dr. Axel Polack is General Partner at JPIF, a life-science oriented early stage venture capital fund. He is also a supervisory board member of HealthUp Sp.zo.o and Survivor Life Ltd and acts as a senior advisor to the Else Kröner-Fresenius-Stiftung (EKFS), a non-profit foundation dedicated to advancing medical research and medical-humanitarian projects Axel has had an impressive three-phase career path with notable achievements in venture capital, business management and biomedical research.
Axel holds a Medical Doctorate degree from the University of Freiberg and a second doctorate (Privatsdozent) in Virology from the Ludwig-Maximilians Universität (LMU) Munich.
Anna Sumeray
Anna Sumeray has over 25 years of experience in the life sciences sector with a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.
Anna’s diverse experiences include the build of a successful European biotech business for a US-based company from the ground up and management of Novartis’s oncology businesses in Finland and Germany. She also has significant M&A and licensing experience and was global head of business development and licensing at Novartis Ophthalmics. She has worked in 13 countries and in 4 languages.
Anna has a BSc (Hons) in Biochemistry from the University of Birmingham, UK and an MBA from INSEAD, Fontainebleau, France.
Jan ter Meulen, MD, Dr. Habil., DTM&H
Dr. Jan ter Meulen is a biotech executive with very broad experience in vaccines and recombinant antibody R&D, as well as immuno-oncology. As a veteran researcher in pharmaceutical, biotechnology and academic settings, Jan brings more than 25 years of operational and strategic research experience to Virometix, including having been the Head of Vaccine Basic Research at Merck & Co., where he was responsible for the entire vaccine discovery pipeline. He also was an International Research Scholar of the Howard Hughes Medical Institute and a consultant for scientific agencies in the US, UK, Germany, France, South Africa and for the European Commission. Jan holds a Medical Doctorate degree from Albert-Ludwigs University of Freiburg, a PhD in Virology from Philipps University of Marburg, and a Diploma in Tropical Medicine from the London School.
Susanne Schultz-Hector, PD Dr. med.
Dr. Susanne Schultz-Hector is an independent university lecturer with extensive knowledge in the field of experimental research. Her professional experience includes: experimental research in radiation biology at Helmholtz-Zentrum München, Massachusetts General Hospital, Boston and LMU Munich; research management at Helmholtz-Gemeinschaft and TU-München; and a member of the management board of Else Kröner-Fresenius-Stiftung as well as member of the supervisory board of GLS Treuhand. She holds a Medical Doctorate degree from the Ludwig-Maximilians Universität (LMU) Munich.
Advisory Board
Prof. Paul-Henri Lambert, MD
Prof. Paul-Henri Lambert, MD, is now associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI), past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO). In 1987, he was appointed as chief of Microbiology and Immunology at the World Health Organization and in 1994, chief of the Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. During this time he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.
Prof. John A. Robinson
Prof. Robinson is a co-founder of Virometix, professor of organic chemistry and former chairman of the Organic Chemistry Institute and the Department of Chemistry and Biochemistry at the University of Zurich. Prof. Robinson is a leading expert in the development of epitope mimetics for drug and vaccine applications. He has published more than 150 papers in major scientific journals and is named as co-inventor on 12 patents. He obtained his Doctorate in Chemistry from Cambridge University, UK.
Jan ter Meulen, MD, Dr. Habil., DTM&H
Dr. Jan ter Meulen is a biotech executive with very broad experience in vaccines and recombinant antibody R&D, as well as immuno-oncology. As a veteran researcher in pharmaceutical, biotechnology and academic settings, Jan brings more than 25 years of operational and strategic research experience to Virometix, including having been the Head of Vaccine Basic Research at Merck & Co., where he was responsible for the entire vaccine discovery pipeline. He also was an International Research Scholar of the Howard Hughes Medical Institute and a consultant for scientific agencies in the US, UK, Germany, France, South Africa and for the European Commission. Jan holds a Medical Doctorate degree from Albert-Ludwigs University of Freiburg, a PhD in Virology from Philipps University of Marburg, and a Diploma in Tropical Medicine from the London School.
Prof. Thorsten Buch
Prof. Thorsten Buch is professor and institute director at the University of Zurich, studying causes for loss of immune tolerance and options for treatment of autoimmune diseases. He started his studies of the immune system more than 25 years ago at the University of California, Davis, US. He obtained his Diploma at the University of Düsseldorf, DE and performed his PhD under Prof. Klaus Rajewsky at the University of Cologne, DE. Before joining the University of Zurich, he was Professor for Medical Microbiology and Immunology at the Technical University Munich. Prof. Buch has published more than 90 papers, is co-inventor on 6 patents, and founder of 2 companies. He is reviewer to multiple journals and research agencies.
Lawrence Segal PhD ERT
Lawrence (Larry) Segal has over 30 years professional experience in regulatory toxicology in the chemical and pharmaceutical Industries and in a Regulatory Agency (Health Canada). He is a Eurotox Registered Toxicologist (ERT). Larry was Director of Nonclinical Toxicology & Pharmacology at GSK Vaccines, where he was responsible for the preparation and review of the non-clinical toxicology sections of all regulatory submissions, interactions with regulatory agencies worldwide, planning and review of GLP toxicity studies, and participation in internal safety monitoring boards and project teams.
Larry is now working as a consultant on freelance basis.
Careers
Working at Virometix
We are hiring!
Senior Research Scientist – Immunologist/Biologist
We are looking for an immunologist/biologist to support our research and lab activities. The person will be based in Athens, Greece, and will be working as part of a team with immunologists, chemists and medical doctors towards the evaluation of nanoparticle-based bacterial vaccines.
Please send your application documents to hr@virometix.com
Are you a team player whose scientific curiosity is complemented by an entrepreneurial spirit, focus and persistence? Do you feel motivated to bring innovative medical solutions to breakthrough?
If so, we encourage you to send your curriculum vitae to hr@virometix.com